BioTime’s CEO Michael West Presents 12 New ACTCellerateTM Cell Lines & New PureStemTM Products Slated for Launch in 2011 at...
October 22 2010 - 9:00AM
Business Wire
BioTime, Inc. (NYSE Amex:BTIM) announced that the Company’s CEO
Dr. Michael West will present data today relating to 12 new cell
lines, differentiation kits, and cell culture media at the GTCbio
4th Advances in Stem Cell Discovery and Development Conference in
San Francisco, California. Dr. West’s presentation titled: “Fate
Space Screening of Clonal Human ES-derived Embryonic Progenitor
Cell Lines” will include a discussion of the Company’s proprietary
bank of more than 140 diverse human cell types made from human
embryonic stem cells, the company’s screening technology for
discovering means of manufacturing human cell types, and the
potential use of these cells for diverse new therapeutics and drug
discovery.
During his lecture, Dr. West will describe the 12 new lines:
B28, EN23, Z3, EN5, RASMO19, EN27, T42, SK47, SM2, SK46, T44, and
SK44 that will be launched beginning November 1, 2010. He also will
disclose new data on the cell lines: SK17 that have the potential
to differentiate into cells that express renin and smooth muscle
cell-related genes characteristic of the juxtaglomerular apparatus
of the kidney, Z2 that when differentiated using a proprietary
protocol expresses relatively high levels of the bone growth factor
genes BMP2 and BMP7 (also known as osteogenic protein-1 (OP-1), and
J16 that expresses preadipocyte markers of interest to researchers
in cosmetic dermatology and type II diabetes.
In addition, Dr. West will disclose for the first time the
Company’s PureStemTM technology, with which the Company plans to
expand its product offerings in calendar year 2011. The PureStemTM
technology utilizes the expression of exogenous transcriptional
regulators to control the differentiation of human embryonic stem
cells and induced plutipotent stem cells, and may potentially
provide many new human cell types needed in regenerative medicine.
BioTime is seeking patent protection for the PureStemTM
technology.
Additional information about these new products will be found at
www.embryome.com beginning on November 1, 2010. Dr. West’s
presentation is available on BioTime’s website at
www.biotimeinc.com.
The annual GTCbio Stem Cell Research & Therapeutics
Conference provides information regarding cutting-edge developments
in all areas of stem cell research including the biology, medicine,
applications, regulations, and business of stem cells. This year’s
conference will address recent developments in pre-clinical and
clinical trials of stem cell therapy, regenerative medicine and
tissue engineering, cancer stem cells, stem cell reprogramming, FDA
and NIH policies regarding funding for stem cell research, and
private funding from the pharmaceutical industry.
About BioTime, Inc.
BioTime, headquartered in Alameda, California, is a
biotechnology company focused on regenerative medicine and blood
plasma volume expanders. Its broad platform of stem cell
technologies is developed through subsidiaries focused on specific
fields of applications. BioTime develops and markets research
products in the field of stem cells and regenerative medicine
through its wholly owned subsidiary Embryome Sciences, Inc.
BioTime’s therapeutic product development strategy is pursued
through subsidiaries that focus on specific organ systems and
related diseases for which there is a high unmet medical need.
BioTime’s majority owned subsidiary Cell Cure Neurosciences, Ltd.
is developing therapeutic products derived from stem cells for the
treatment of retinal and neural degenerative diseases. Cell Cure's
minority shareholder Teva Pharmaceutical Industries has optioned
its OpRegenTM retinal cell product for use in the treatment of
Age-related Macular Degeneration (AMD). BioTime's subsidiary
OrthoCyte Corporation is developing therapeutic applications of
stem cells to treat orthopedic diseases and injuries. Another
subsidiary, OncoCyte Corporation, focuses on the therapeutic
applications of stem cell technology in cancer. BioTime’s Singapore
subsidiary, ES Cell International Pte Ltd, has been at the
forefront of advances in human embryonic stem (“hES”) cell
technology, having been one of the earliest distributors of hES
cell lines to the research community. ESI has produced
clinical-grade human embryonic stem cell lines that were derived
following principles of good manufacturing practice and currently
offers them for potential use in therapeutic product development.
In addition to its stem cell products, BioTime develops blood
plasma volume expanders, blood replacement solutions for
hypothermic (low temperature) surgery, and technology for use in
surgery, emergency trauma treatment and other applications.
BioTime’s lead product, Hextend®, is a blood plasma volume expander
manufactured and distributed in the U.S. by Hospira, Inc. and in
South Korea by CJ CheilJedang Corp. under exclusive licensing
agreements. Additional information about BioTime, Embryome
Sciences, Cell Cure, OrthoCyte, OncoCyte, BioTime Asia, and ESI can
be found on the web at www.biotimeinc.com.
Forward-Looking Statements
Statements pertaining to future financial and/or operating
results, future growth in research, technology, clinical
development, and potential opportunities for the company and its
subsidiaries, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management constitute forward-looking statements. Any statements
that are not historical fact (including, but not limited to
statements that contain words such as “will,” “believes,” “plans,”
“anticipates,” “expects,” “estimates”) should also be considered to
be forward-looking statements. Forward-looking statements involve
risks and uncertainties, including, without limitation, risks
inherent in the development and/or commercialization of potential
products, uncertainty in the results of clinical trials or
regulatory approvals, need and ability to obtain future capital,
and maintenance of intellectual property rights. Actual results may
differ materially from the results anticipated in these
forward-looking statements and as such should be evaluated together
with the many uncertainties that affect the company’s business,
particularly those mentioned in the cautionary statements found in
the company’s Securities and Exchange Commission filings. The
company disclaims any intent or obligation to update these
forward-looking statements.
To receive ongoing BioTime corporate communications, please
click on the following link to join our email alert list:
http://www.b2i.us/irpass.asp?BzID=1152&to=ea&s=0